Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Literature DB >> 14532159

Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

B Foxwell¹, E Andreakos, F Brennan, M Feldmann, C Smith, M Conron.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2003 PMID： 14532159 PMCID： PMC1766755 DOI： 10.1136/ard.62.suppl_2.ii90

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

35 in total

1. Nuclear factor-kappaB activation in alveolar macrophages requires IkappaB kinase-beta, but not nuclear factor-kappaB inducing kinase.

Authors: Matthew Conron; Evangelos Andreakos; Panagiotis Pantelidis; Clive Smith; Huw L C Beynon; Roland M Dubois; Brian M J Foxwell
Journal: Am J Respir Crit Care Med Date: 2002-04-01 Impact factor: 21.405

Review 2. Anti-TNF therapy for other inflammatory conditions.

Authors: Z Tutuncu; G J Morgan; A Kavanaugh
Journal: Clin Exp Rheumatol Date: 2002 Nov-Dec Impact factor: 4.473

Review 3. Cytokines and anti-cytokine biologicals in autoimmunity: present and future.

Authors: Evangelos T Andreakos; Brian M Foxwell; Fionula M Brennan; Ravinder N Maini; Marc Feldmann
Journal: Cytokine Growth Factor Rev Date: 2002 Aug-Oct Impact factor: 7.638

4. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors: P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal: Lancet Date: 2000-07-29 Impact factor: 79.321

5. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors: D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal: N Engl J Med Date: 2000-03-16 Impact factor: 91.245

6. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors: J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal: Lancet Date: 2002-04-06 Impact factor: 79.321

Review 7. TNF-R1 signaling: a beautiful pathway.

Authors: Guoqing Chen; David V Goeddel
Journal: Science Date: 2002-05-31 Impact factor: 47.728

8. The specificities of protein kinase inhibitors: an update.

Authors: Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal: Biochem J Date: 2003-04-01 Impact factor: 3.857

9. Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction.

Authors: Evangelos Andreakos; Clive Smith; Claudia Monaco; Fionula M Brennan; Brian M Foxwell; Marc Feldmann
Journal: Blood Date: 2002-09-19 Impact factor: 22.113

Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

1. Nuclear factor-kappaB activation in alveolar macrophages requires IkappaB kinase-beta, but not nuclear factor-kappaB inducing kinase.

Review 2. Anti-TNF therapy for other inflammatory conditions.

Review 3. Cytokines and anti-cytokine biologicals in autoimmunity: present and future.

4. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

5. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

6. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Review 7. TNF-R1 signaling: a beautiful pathway.

8. The specificities of protein kinase inhibitors: an update.

9. Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction.

10. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.

1. UP446, analgesic and anti-inflammatory botanical composition.

Review 2. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.

Review 3. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells.

Review 4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.